Abstract
Catestatin was discovered as a potent inhibitor of catecholamine secretion and plays important roles in the cardiovascular system. Our previous study demonstrates a close relationship between catestatin levels and prognosis of ST-elevation myocardial infarction (STEMI). Using the same population, the goal of this study is to investigate the ability of catestatin to predict left ventricular (LV) remodeling in STEMI patients. 72 patients and 30 controls were included. Catestatin was sampled after admission to the emergency room (ER), at day3 (D3), and day7 (D7) after STEMI. Echocardiography was performed at D3 and after 65 months for evaluation of LVEDD, EF, IVS, LVPW, E, A, E’, E/A, and E/E’. The changes of these parameters from D3 to 65 months were used to reflect the changes of ventricular structure and function. We found that plasma catestatin levels at D3 were highly correlated with the changes of LVEDD, EF, E, A, E’, E/A, as well as E/E’. Patients with higher catestatin levels developed worse ventricular function during the follow-up period. Single-point catestatin was effective to predict LVEDD change. And concurrently increasing catestatin and NT-proBNP levels predicted the highest risk of LV remodeling. This study suggests an important prognostic information of catestatin on LV remodeling.
Highlights
In early studies, researchers demonstrated that the degree of chamber remodeling was highly associated with the extent of myocardial injury[3] and factors like anterior infarct location[5] and patency of the infarct-related artery[6], etc
As one of the strongest predictors of subsequent mortality, left ventricular (LV) remodeling occurs in an appreciable proportion of patients with AMI, even those successfully treated with primary percutaneous coronary intervention (pPCI)
A major challenge in clinic is to discriminate between patients with reversible dysfunction and those who will experience little functional recovery accompanied by LV remodeling, which necessitates the development of new strategies to predict adverse events at early stages
Summary
Researchers demonstrated that the degree of chamber remodeling was highly associated with the extent of myocardial injury[3] and factors like anterior infarct location[5] and patency of the infarct-related artery[6], etc. Catestatin is a 21-amino acid peptide generated endogenously by proteolytic cleavage of its precursor chromogranin A (CHGA)[10], which is co-stored and co-released with catecholamines. It has been intensively studied in cardiovascular system in recent years, which displayed potent vasodilatory effect in both rate and human[11,12]. Our previous studies indicated that catestatin had a predictive effect to detect stage B heart failure[15] and was correlated to prognosis of patients with AMI16 Based on these functions in the cardiovascular system, we hypothesized that catestatin level might be useful for the diagnosis and determination of LV remodeling following AMI. Correspondence and requests for materials should be addressed to W.G
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
